CeriBell (NASDAQ:CBLL) Shares Gap Down After Insider Selling

Shares of CeriBell, Inc. (NASDAQ:CBLL) gapped down before the market opened on Wednesday after an insider sold shares in the company. The stock had previously closed at $19.90, but opened at $18.82. CeriBell shares last traded at $18.9310, with a volume of 119,076 shares changing hands.

Specifically, CEO Xingjuan Chao sold 2,084 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $19.79, for a total value of $41,242.36. Following the completion of the sale, the chief executive officer owned 725,164 shares in the company, valued at $14,350,995.56. This represents a 0.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Josef Parvizi sold 16,714 shares of the business’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $20.27, for a total value of $338,792.78. Following the completion of the transaction, the director directly owned 722,652 shares of the company’s stock, valued at approximately $14,648,156.04. The trade was a 2.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing.

Analyst Ratings Changes

A number of analysts recently issued reports on CBLL shares. TD Cowen reissued a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. JPMorgan Chase & Co. decreased their price objective on CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Canaccord Genuity Group boosted their target price on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Finally, BTIG Research reaffirmed a “buy” rating and set a $30.00 price target on shares of CeriBell in a research report on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, CeriBell currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

CeriBell Stock Performance

The company has a quick ratio of 12.25, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. The stock’s fifty day moving average is $21.17 and its two-hundred day moving average is $16.21. The firm has a market capitalization of $692.58 million, a price-to-earnings ratio of -12.70 and a beta of 1.03.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million. CeriBell had a negative net margin of 59.97% and a negative return on equity of 31.77%. On average, analysts predict that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Hedge Funds Weigh In On CeriBell

Institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its position in shares of CeriBell by 3,971.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after buying an additional 1,231 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in CeriBell in the 3rd quarter valued at $33,000. CWM LLC lifted its holdings in CeriBell by 1,178.5% during the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after purchasing an additional 1,697 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its position in CeriBell by 97.5% during the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after purchasing an additional 1,256 shares during the period.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.